KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Common Equity (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed Common Equity for 17 consecutive years, with $81.5 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 14.06% to $81.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.5 billion through Dec 2025, up 14.06% year-over-year, with the annual reading at $81.5 billion for FY2025, 14.06% up from the prior year.
  • Common Equity hit $81.5 billion in Q4 2025 for Johnson & Johnson, up from $79.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $81.5 billion in Q4 2025 to a low of $63.3 billion in Q1 2021.
  • Historically, Common Equity has averaged $73.0 billion across 5 years, with a median of $71.5 billion in 2024.
  • Biggest five-year swings in Common Equity: increased 16.98% in 2022 and later dropped 10.46% in 2023.
  • Year by year, Common Equity stood at $70.3 billion in 2021, then grew by 6.16% to $74.6 billion in 2022, then decreased by 7.81% to $68.8 billion in 2023, then grew by 3.95% to $71.5 billion in 2024, then grew by 14.06% to $81.5 billion in 2025.
  • Business Quant data shows Common Equity for JNJ at $81.5 billion in Q4 2025, $79.3 billion in Q3 2025, and $78.5 billion in Q2 2025.